Core Viewpoint - The company Maiwei Biotech has developed a unique targeted monoclonal antibody, 9MW3011, for the treatment of Polycythemia Vera (PV), which is the only one of its kind globally [1] Group 1: Product Development - The 9MW3011 antibody has received external licensing for collaboration, with the company responsible for development and commercialization in Greater China and Southeast Asia [1] - The partner DISCMEDICINE, INC. is advancing the product in other regions and has obtained "Fast Track Designation" (FTD) and "Orphan Drug Designation" (ODD) from the FDA [1] Group 2: Clinical Trials - The Phase II clinical study targeting PV patients is set to complete its first dosing in the United States by September 2025, marking a significant milestone in the collaboration [1] - PV has been included in the second batch of rare disease catalog published by the National Health Commission in September 2023, indicating ongoing efforts to advance clinical enrollment in both China and the U.S. [1]

国泰海通证券股份有限公司 关于迈威（上海）生物科技股份有限公司 调整部分募投项目内部投资结构的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为迈 威（上海）生物科技股份有限公司（以下简称"迈威生物"、"公司"或"发行人"） 首次公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理 办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》等 有关法律法规和规范性文件的要求，就迈威生物调整部分募投项目内部投资结构 的事项进行了审慎核查，并发表如下核查意见： 一、募投项目内部投资结构调整的概述 （一）募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意迈威（上海）生物科技股份 有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3859号），公司首次 向社会公开发行人民币普通股99,900,000股，每股发行价格为人民币34.80元，募 集资金总额为人民币3,476,520,000.00元，募集资金净额为人民币3,303,432,172.40 元，其中超募资金金额为人民币323,432,172.40元。上述资金已于2022年1月10日 全部到位，安 ...

证券代码：688062 证券简称：迈威生物 公告编号：2026-004 迈威（上海）生物科技股份有限公司 关于公司调整部分募投项目内部投资结构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为规范公司募集资金管理和使用，保护投资者权益，公司设立了相关募集资 金专项账户。募集资金到账后，已全部存放于经公司董事会批准开设的募集资金 专项账户内，公司及全资子公司已与保荐机构、存放募集资金的商业银行签署了 募集资金监管协议。 1、募集资金投资项目基本情况表 单位：万元 币种：人民币 重要内容提示： 募投项目内部投资结构调整情况：迈威（上海）生物科技股份有限公司 （以下简称"迈威生物"或"公司"）拟对 2022 年首次公开发行股份募投项目"抗 体药物研发项目"中的内部投资结构进行金额调整，拟减少 9MW0311、9MW0321、 8MW0511、9MW1111、9MW1411、6MW3211 项目的募集资金投入，并将减少 部分用于增加 9MW2821 项目的募集资金投入，本次调整不涉及"抗体药物研发 项目"及其他募投项目计划投入 ...

| | | 迈威（上海）生物科技股份有限公司 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，保证股东在迈威（上海）生物科技股份有 限公司（以下简称"公司"）依法行使股东权利，确保 2026 年第一次临时股东 会会议的正常秩序和议事效率，根据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）、中国证 券监督管理委员会（以下简称"中国证监会"）《上市公司股东会规则》以及 《迈威（上海）生物科技股份有限公司公司章程》（以下简称"《公司章程》"） 《迈威（上海）生物科技股份有限公司股东会议事规则》等有关规定，特制定 本须知，请全体出席股东会的人员自觉遵守。 一、 为确认出席会议的股东或代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者予以配合。 迈威（上海）生物科技股份有限公司 2026 年第一次临时股东会会议资料 2026 年 2 月 二、 经公司审核后符合参加本次股东会条件的股东（含股东代理人）、董 事、高级管理人员及其他出席人员方可出席本次会议；公司有权拒绝不符合条 件的人士进入会场。 三、 会议 ...

证券代码：688062 证券简称：迈威生物 公告编号：2026-005 迈威（上海）生物科技股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2026 年 2 月 13 日 15 点 00 分 召开地点：上海市浦东新区李冰路 576 号创想园 3 号楼 103 会议室 （五） 网络投票的系统、起止日期和投票时间。 至2026 年 2 月 13 日 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 股东会召开日期：2026年2月13日 ...

Group 1 - The core point of the news is that Maiwei Biotech's stock has experienced a decline of 5.01%, with a current price of 38.28 CNY per share and a total market capitalization of 15.297 billion CNY [1] - Maiwei Biotech, established on May 12, 2017, specializes in the research, production, and sales of therapeutic biological products, with 99.91% of its revenue coming from product sales [1] - The trading volume for Maiwei Biotech reached 288 million CNY, with a turnover rate of 3.63% [1] Group 2 - According to data, the Shenyuan Lingxin Fund holds a significant position in Maiwei Biotech, with the Shenyuan Lingxin Medical Pioneer Stock A fund (005433) owning 288,500 shares, representing 4.98% of the fund's net value [2] - The Shenyuan Lingxin Medical Pioneer Stock A fund has reported a floating loss of approximately 582,800 CNY today [2] - The fund has a total asset size of 1.05 billion CNY and has experienced a year-to-date return of 6.17%, ranking 2698 out of 5579 in its category [2]

Core Viewpoint - Maiwei Biotech (688062) is expected to continue incurring losses in 2025, with a projected net profit attributable to shareholders ranging from -900 million to -995 million yuan compared to the previous year [1] Financial Performance - The company anticipates a significant increase in revenue from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISC MEDICINE, INC. [1] - There is a notable growth in drug sales revenue compared to the same period last year [1] Cost and Investment - As commercialization expands, both operating costs and sales expenses are expected to rise correspondingly [1] - The company maintains a high level of research and development investment, with multiple innovative drugs in critical trial phases [1]

Core Viewpoint - Maiwei Biotech announced an expected narrowing of losses for the fiscal year 2025, projecting a net profit attributable to the parent company of between -900 million to -994.5 million yuan, compared to a loss of -1,043.92 million yuan in the previous year [2] Financial Performance - The company anticipates a net profit attributable to the parent company, excluding non-recurring gains and losses, to be between -905 million to -999.5 million yuan [2]

Core Viewpoint - Maiwei Biotech has announced a profit forecast for 2025, projecting a net loss attributable to shareholders of the parent company between 900 million to 995 million yuan [1] Financial Performance - The company expects a net loss attributable to shareholders after deducting non-recurring gains and losses to be between 905 million to 1 billion yuan [1]

Core Viewpoint - Maiwei Biotech (688062.SH) is expected to continue reporting a net loss attributable to shareholders in 2025, with projected losses ranging from -900 million to -994.5 million yuan [1] Financial Performance - The company's operating revenue is anticipated to increase significantly compared to the previous year, primarily due to substantial income recognized from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISCMEDICINE, INC., along with a notable rise in drug sales revenue [1] - The expected net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between -905 million and -999.5 million yuan [1] Cost and Investment Factors - As commercialization expands, both operating costs and sales expenses are expected to rise correspondingly [1] - The company is maintaining a high level of research and development investment, with multiple innovative drugs currently in critical trial phases [1]